Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 207-214

  Yim, Kein Leong ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

Everolimus; mTOR; Neuroendocrine; Pancreatic; Signaling; Targeted

Indexed keywords

BEVACIZUMAB; CHROMOGRANIN A; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PASIREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; SOMATOSTATIN RECEPTOR 2; TEMSIROLIMUS;

ANEMIA; CANCER GRADING; CANCER SURVIVAL; CARCINOID; DIARRHEA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEVER; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; PANCREATIC NEUROENDOCRINE TUMOR; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA;

EID: 84930482060     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S25979     Document Type: Review

References (39)

1. Yao JC, Hassan M, Phan A, etal. One hundred years after "carcinoid:" epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072.
2. Solorzano CC, Lee JE, Pisters PW, etal. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130(6):1078-1085.
3. Raymond E, Dahan L, Raoul JL, etal. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-513.
4. Yao JC, Phan AT, Chang DZ, etal. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311-4318.
5. Yao JC, Lombard-Bohas C, Baudin E, etal. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69-76.
6. Yao JC, Shah MH, Ito T, etal. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
7. Yim KL. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocrine. 2011;40(2):181-186.
8. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16(4):525-537.
9. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6(9):729-734.
10. Smrz D, Kim MS, Zhang S, etal. mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood. 2011;118(26):6803-6813.
11. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin ME. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol. 2006;18(5):355-360.
12. Missiaglia E, Dalai I, Barbi S, etal. Pancreatic endocrine tumors: expression profiling evidences a role for Akt-mTOR pathway. J Clin Oncol. 2010;28(2):245-255.
13. Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, etal. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr. 1999;158(4):284-287.
14. Yoshida A, Hatanaka S, Ohi Y, Umekita Y, Yoshida H. von Recklinghausen's disease associated with somatostatin-rich duodenal carcinoid (somatostatinoma), medullary thyroid carcinoma and diffuse adrenal medullary hyperplasia. Acta Pathol Jpn. 1991;41(11):847-856.
15. Yim KL, Cunningham D. Targeted drug therapies and cancer. Recent Results Cancer Res. 2011;185:159-171.
16. Grozinsky-Glasberg S, Franchi G, Teng M, etal. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology. 2008;87(3):168-181.
17. Zitzmann K, De Toni EN, Brand S, etal. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology. 2007;85(1):54-60.
18. Thimmaiah KN, Easton J, Huang S, etal. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways. Cancer Res. 2003;63(2):364-374.
19. Beuvink I, Boulay A, Fumagalli S, etal. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120(6):747-759.
20. Fumarola C, La Monica S, Alfieri RR, Borra E, Guidotti GG. Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ. 2005;12(10):1344-1357.
21. O'Reilly KE, Rojo F, She QB, etal. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500-1508.
22. von Wichert G, Jehle PM, Hoeflich A, etal. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 2000;60(16):4573-4581.
23. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83-95.
24. Duran I, Kortmansky J, Singh D, etal. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95(9):1148-1154.
25. Rinke A, Muller HH, Schade-Brittinger C, etal. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656-4663.
26. Panzuto F, Di Fonzo M, Iannicelli E, etal. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. 2006;17(3):461-466.
27. Arnold R, Rinke A, Klose KJ, etal. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761-771.
28. Bruns CJ, Koehl GE, Guba M, etal. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res. 2004;10(6):2109-2119.
29. Guba M, von Breitenbuch P, Steinbauer M, etal. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128-135.
30. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev. 2007;26(3-4):611-621.
31. Lane HA, Wood JM, McSheehy PM, etal. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15(5):1612-1622.
32. Yao JC, Phan AT, Fogleman D, etal. Randomized run-in study of bevacizumab (B) and everolimus (E) in low-to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker [abstract]. J Clin Oncol. 2010;28(Suppl 15):4002.
33. Saltz L, Trochanowski B, Buckley M, etal. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72(1):244-248.
34. Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res. 1989;9(4):889-891.
35. Carracedo A, Ma L, Teruya-Feldstein J, etal. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065-3074.
36. Villaume K, Blanc M, Gouysse G, etal. VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/Akt/mTOR pathway. Neuroendocrinology. 2010;91(3):268-278.
37. Zatelli MC, Piccin D, Vignali C, etal. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer. 2007;14(1):91-102.
38. Petersenn S, Schopohl J, Barkan A, etal. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95(6):2781-2789.
39. Kvols L, Wiedenmann B, Oberg K, etal. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study [abstract]. J Clin Oncol. 2006;24(Suppl 18):4082.